50 Chapter 3 Table 1. Baseline characteristics and demographics (continued) All patients Baseline [18F]FDG-uptake** Baseline [89Zr)Zr-DFO-girentuximab uptake** (n = 40) Low uptake group (n = 20) High uptake group (n = 20) Low uptake group (n = 20) High uptake group (n=20) W&W criteria, favorable 21 (52.5) 14 (61) 7 (42) 14 (70) 7 (35) Sum of diameter (cm) (median, range) 7.7 (1.0 - 66.2) 3.5 (1.0 - 41.9) 11.3 (3.7 - 66.2) 4.9 (1.0 - 66.2) 11.3 (2.5 - 41.9) If [18F]FDG-positive, geometric mean per patient, (median, range) # 4.8 (1.9 -12.2) - - 3.1 (1.9 - 3.7) 6.7 (3.9 - 12.2) If [89Zr]Zr-DFO-girentuximab positive, geometric mean per patient, (median, range) # 15.4 (5.0 -104.8) 9.3 (5.0 - 12.8) 20.1 (14.1 - 104.8) - - * Two patients previously received local radiotherapy with curative intent. One patient underwent a metastasectomy of the only present metastasis with curative intent ** Patients with no PET-positive and RECIST measurable lesions were interpreted as having a very low SUVmax value and grouped accordingly. The per-patient uptake is expressed as the geometric mean SUVmax of all RECIST measurable PET-positive lesions. Patients are grouped based on the median geometric mean SUVmax of [ 18F]FDG- or [89Zr]Zr-DFO-girentuximab, respectively. (LLN= lower limit of normal, ULN= upper limit of normal) † Data available for 33 of 40 (83%) patients ◊ Based on only RECIST-positive lesions as visualized by CT. Lesions were detected in lung, lymph nodes, bone, adrenal gland, kidney, and soft tissue. # Data available for 34 (85%) patients, based on RECIST-positive lesions only
RkJQdWJsaXNoZXIy MTk4NDMw